AOD-9604

AOD 9604 — HGH-Fragment Peptides

AOD 9604 is a synthetic fragment of human growth hormone (aa 176–191) engineered to isolate lipolytic (fat-breaking) activity without stimulating IGF-1 production or broader anabolic pathways. [1] However, clinical development for obesity was terminated in 2007 due to poor efficacy in human trials. [3] It remains available exclusively as a research chemical with “not for human consumption” labeling. Licensed practitioners can contact Medical Spa Rx’s support team for guidance on sourcing from qualified suppliers and accessing verifiable purity documentation.

AOD 9604: Regulatory Context & Research Background

AOD 9604 is a synthetic fragment of human growth hormone corresponding to amino acids 176–191, originally developed through research associated with Monash University and Metabolic Pharmaceuticals. [1][3] The peptide was engineered to isolate the fat-metabolizing and lipolytic effects of HGH while avoiding anabolic activity and IGF-1 stimulation. [1] Research interest initially focused on fat loss, lipolysis, and body composition rather than hormone replacement or generalized endocrine stimulation. [1][2]

The compound received FDA GRAS (Generally Recognized As Safe) status in 2014 as a food ingredient only. This is a food-safety designation and not drug approval, not efficacy confirmation, and not a legal pathway for weight-loss products. GRAS status does not make AOD 9604 a legally marketed weight-loss product in the United States. [4]

In December 2024, the FDA’s Pharmacy Compounding Advisory Committee declined to include AOD 9604 on the 503A bulk drug substances list, meaning compounding pharmacies cannot legally produce it for individual prescriptions. [4] It is not on the current 503A list and has no active FDA pathway in the United States. [4].

As of mid 2026, AOD 9604 is classified as a research peptide only.

How the AOD 9604 Peptide Works: Mechanism & Effect on HGH Levels

AOD 9604 functions differently from conventional human growth hormone products and growth hormone secretagogues. Research-extrapolated evidence suggests the peptide interacts with beta-3 adrenergic receptor pathways in adipocytes, activating hormone-sensitive lipase (HSL) and promoting lipolysis. [1] This mechanism underlies its characterization as a fat-burning peptide focused on adipose metabolism rather than generalized endocrine stimulation. [1]

Preclinical and practitioner-reported observations also suggest a dual-action effect involving increased fat breakdown and reduced lipogenesis, potentially limiting the formation of new fat cells while supporting fat oxidation. [1] Unlike full-length HGH, AOD 9604 does not appear to significantly activate the growth hormone receptor or elevate IGF-1 levels. [1][3]

Human trial findings from Metabolic Pharmaceuticals’ Phase 2 studies showed no meaningful increase in IGF-1 with oral administration, differentiating the peptide from secretagogues such as Sermorelin and CJC-1295. [3] Phase 2 data and practitioner observations also suggest no significant glucose disruption or anti-insulin effects commonly associated with systemic HGH therapy. [3]

AOD 9604 Benefits & Evidence Tiers

Research interest in AOD 9604 focuses entirely on targeted adipose metabolism rather than generalized endocrine stimulation. [1][2] The quality of evidence varies dramatically by application:

Fat Loss Support

• Evidence Tier: Human Phase 2b (Terminated Development)
• Conclusion: Current human evidence does not support AOD 9604 as an effective fat-loss agent.

An early, small 12-week trial showed a modest weight reduction of 1.8–2.6 kg over placebo, but these findings were invalidated by the failure of the larger 536-subject trial. [3]

Metabolic Safety Profile

• Evidence Tier: Human Trial + Practitioner-Reported
• Conclusion: Targeted metabolic activity without systemic growth hormone exposure.

Unlike full-length HGH, human trial data indicate that oral AOD 9604 does not activate the growth hormone receptor, spike insulin-like growth factor 1 (IGF-1), or cause the glucose disruptions and anti-insulin effects common to standard systemic HGH therapies. [3]

Experimental Applications

• Tissue & Cartilage Support (In Vitro / Preclinical): Laboratory studies using Saos-2 cell lines have explored regenerative signaling pathways. There are no robust human data confirming cartilage repair or improvement in osteoarthritis. [3]
• Body Composition & Exercise (Practitioner-Reported / Extrapolated): Sports medicine discussions note potential fat oxidation without fluid retention. [1] Claims regarding athletic endurance or accelerated muscle recovery are entirely unvalidated.

AOD 9604 Dosage, Administration & Stacking

No FDA-approved injectable protocol exists for AOD 9604. [4] All dosing information below is practitioner-reported and research-extrapolated, not clinically validated, and should not be interpreted as standard or recommended practice.

Subcutaneous protocols reported by practitioners commonly range from 250–500 mcg daily and are often administered fasted, in the morning, or before exercise. Phase 2 clinical studies evaluated oral dosing at 1–5 mg daily; injectable equivalence is unknown and cannot be assumed. [3] Reconstitution typically involves bacteriostatic water under sterile conditions, with storage at 2–8°C and protection from light recommended after mixing.

Practitioner-reported cycle lengths generally range from 8 to 16 weeks. Long-term injectable safety data beyond the available Phase 2b investigations remain limited, making individualized clinical assessment essential when evaluating AOD 9604 peptide dosing protocols. [3]

Stacking AOD 9604

These combinations are entirely research-extrapolated with no clinical validation. No safety or efficacy data exist for stacking AOD 9604 with other peptides. The mechanistic rationales below reflect practitioner-reported reasoning only and should not be interpreted as evidence of benefit or safety.

AOD 9604 + CJC-1295

Practitioners sometimes discuss stacking AOD 9604 with CJC-1295 because the two compounds target different physiological pathways. AOD 9604 functions as a direct HGH fragment focused on adipocyte metabolism [1], whereas CJC-1295 acts as a growth hormone-releasing hormone analog that stimulates endogenous GH pulsatility.

This combination is framed by some practitioners as a complementary strategy pairing direct lipolytic activity with broader endocrine signaling. Any such protocol should be understood as entirely research-extrapolated with no clinical validation.

AOD 9604 + Ipamorelin

Ipamorelin is a ghrelin receptor agonist and growth hormone secretagogue occasionally discussed alongside AOD 9604 in practitioner research contexts. The proposed rationale involves pairing targeted adipocyte-level activity with endogenous GH release and recovery-oriented signaling.

Because Ipamorelin influences pituitary activity, whereas AOD 9604 does not [1][3], researchers should clearly distinguish between direct fragment activity and hormonal stimulation when evaluating this combination. No validated dosing or safety data exist for this pairing.

AOD 9604 + Sermorelin

Some practitioners discuss combining AOD 9604 with Sermorelin in research protocols focused on body composition or metabolic evaluation. Sermorelin stimulates endogenous growth hormone production via GHRH pathways, whereas AOD 9604 provides targeted fat-metabolism activity without directly increasing IGF-1 levels.

This mechanistic distinction is sometimes cited as a rationale for pairing the two compounds in research settings. Professionals reviewing this approach may also compare available literature on Sermorelin when evaluating broader GH-axis research strategies.

Legal Status & Safety Profile of AOD 9604

As of mid 2026, AOD 9604 is not FDA-approved in the United States for obesity treatment, metabolic disease, or any therapeutic application. [4] In December 2024, the FDA’s Pharmacy Compounding Advisory Committee declined to add it to the 503A bulk drug substances list, meaning compounding pharmacies cannot legally produce it for individual prescriptions. [4] It is not on the current 503A list and has no active FDA pathway in the United States. [4]

Key regulatory considerations include:

• United States: Research compound only; not FDA-approved; not on the 503A bulk drug substances list as of December 2024 [4]
• Australia: Schedule 4 substance under the TGA, requiring prescription oversight
• Canada and the EU: No formal marketing authorization for therapeutic use
• WADA: AOD 9604 is prohibited under the 2025/2026 WADA Prohibited List, listed under growth hormone fragments (including AOD 9604 and hGH 176–191); competitive athletes should be advised that use carries a ban risk

Available safety data remain limited. [3] During Phase 2 oral trials, AOD 9604 peptide side effects were generally mild, with no major serious adverse events reported. [3] Injection-site redness or irritation may occur with subcutaneous administration. [3] Long-term injectable safety data remain lacking, and all dosing practices are practitioner-reported and extrapolated from research. [3]

Professionals who purchase AOD 9604 for research use should prioritize purity testing, storage standards, and sourcing transparency when evaluating suppliers.

Where Can Practitioners Buy AOD 9604 Online?

AOD 9604 is a research-grade compound available for purchase by qualified professionals only and is not intended for personal, therapeutic, or clinical use. Practitioners looking to order AOD 9604 from a verified research-grade supplier should source only from vendors who can provide verifiable purity documentation, LOT number traceability, and a certificate of analysis for each batch. These standards help ensure compound integrity and support responsible research practices.

Medical Spa Rx’s professional support team offers sourcing guidance and documentation support to help licensed professionals identify qualified suppliers and evaluate wholesale pricing options when researching where to buy AOD 9604 online. Practitioners are encouraged to contact Medical Spa Rx’s professional support team directly for guidance and direction on supplier standards, documentation requirements, and research-grade sourcing considerations.

AOD 9604 vs. Tesamorelin

AOD 9604 and Tesamorelin differ significantly in their mechanisms and regulatory statuses. AOD 9604 is a fragment of human growth hormone designed to promote lipolysis without significantly elevating IGF-1[1], whereas Tesamorelin is a GHRH analog that stimulates endogenous growth hormone release and increases IGF-1 production. [2] Tesamorelin holds FDA approval for HIV-associated lipodystrophy, while AOD 9604 remains a research compound without therapeutic approval and with no active FDA pathway.[4]

Practitioners may consider AOD 9604 in research contexts where minimizing GH-axis stimulation or systemic endocrine effects is a priority, particularly in off-label body-composition discussions focused on targeted fat oxidation and metabolic safety. Researchers who choose to buy Tesamorelin for comparative protocol work will find its GHRH-based mechanism and approved regulatory standing offer a distinct reference point alongside AOD 9604.[1][3]

AOD 9604 vs. Sermorelin

AOD 9604 differs from Sermorelin primarily in endocrine activity and biological mechanism. Sermorelin is a GHRH analog that stimulates pituitary growth hormone release and downstream IGF-1 production, whereas AOD 9604 is an HGH fragment with more targeted adipose-related activity.[1][3] Sermorelin’s short half-life supports physiologic GH pulsatility, whereas AOD 9604 focuses on direct lipolytic signaling rather than endocrine amplification.

Practitioners may consider AOD 9604 in research contexts where targeted fat oxidation is the goal and broader GH-axis stimulation is undesirable. Researchers who choose to buy Sermorelin for endocrine-focused protocols will find its pituitary stimulation profile provides a useful mechanistic contrast when designing comparative research.[3]

FAQs

1. What is AOD 9604, and how does it differ from HGH?

AOD 9604 isolates the C-terminal lipolytic domain of HGH (aa 176–191). It retains the fat-metabolizing actions of the parent hormone but lacks the structural features required to activate the growth hormone receptor or elevate IGF-1 levels, thereby avoiding systemic side effects such as fluid retention and insulin resistance.

2. What does AOD 9604 do for fat loss?

Early clinical research showed modest weight reduction in a 12-week trial, but a subsequent 24-week trial with 536 subjects failed to meet its primary efficacy endpoint, and development was terminated in 2007. Current evidence does not support AOD 9604 as an effective fat-loss agent in humans. All injectable dosing practices remain practitioner-reported and research-extrapolated, not clinically validated.

3. Is AOD 9604 legal to buy?

As of June 2026, AOD 9604 is not FDA-approved in the United States and is classified as a research compound only. In December 2024, the FDA’s Pharmacy Compounding Advisory Committee declined to add it to the 503A bulk drug substances list. AOD 9604 is also prohibited under the WADA 2025/2026 Prohibited List. Practitioners and researchers should verify jurisdiction-specific regulations before evaluating sourcing or protocol considerations.

4. What is the AOD 9604 dosage?

No FDA-approved dosing protocol exists for AOD 9604. Practitioner-reported injectable protocols commonly range from 250–500 mcg daily via subcutaneous administration, while Phase 2 clinical trials studied oral doses of 1–5 mg daily. Injectable equivalence to oral dosing is unknown. All protocols should be considered research-extrapolated and evaluated through individualized clinical assessment.

5. How does AOD 9604 compare to Tesamorelin?

AOD 9604 acts as a standalone hormone fragment that directly triggers fat cells. In contrast, Tesamorelin is a GHRH analogue that signals the pituitary gland to increase total endogenous growth hormone output, raising systemic IGF-1 levels. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, whereas AOD 9604 lacks therapeutic clearance.

6. Can AOD 9604 be stacked with other peptides?

Practitioner-reported protocols sometimes discuss combining AOD 9604 with peptides such as CJC-1295, Ipamorelin, or Sermorelin. No safety or efficacy data exist for any of these combinations, and all are entirely research-extrapolated. Any such protocol should be evaluated strictly within a research context and according to the specific parameters of the research design.

Sources

1. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. doi:10.1210/endo.142.12.8522
2. Misra M. Obesity Pharmacotherapy: Current perspectives and future directions. Curr Cardiol Rev. 2013;9(1):33-54. doi:10.2174/157340313805076322
3. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15. doi:10.4021/jem.v3i1-2.157
4. US Food and Drug Administration. Certain Bulk Drug Substances Used in Compounding May Present Significant Safety Risks. Updated April 21, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.